NovoCure Limited (NVCR) AI Stock Analysis

NovoCure Limited develops, manufactures, and commercializes tumor treating fields (TTFields) devices that use alternating electrical fields to disrupt cancer cell division. Its primary commercial products include Optune for glioblastoma and Optune Lua for malignant pleural mesothelioma, marketed across the United States, Europe, the Middle East, Africa, Japan, and Greater China. Founded in 2000 and based in Saint Helier, Jersey, the oncology company employs 1,605 people. NovoCure conducts clinical trials evaluating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer, brain metastases, gastric cancer, and liver cancer.

Between FY2021 and FY2025, revenue grew at a 5-year CAGR of 5.8%, rising from $535.0M in FY2021 to $655.4M in FY2025, including 8.3% annual growth in FY2025. Gross margins remained high across this span, recording 78.5% in FY2021 and 74.5% in FY2025. Operating margins were consistently negative, reaching -23.5% in FY2025 alongside a net loss of $136.2M and an EPS of -$1.22, influenced by $224.5M in R&D expense. For the trailing twelve months ended June 30, 2026, revenue stood at $699.2M with an operating margin of -5.8% and net EPS of -$1.30. In the latest quarter ended June 30, 2026, revenue rose 15.6% year-over-year, while quarterly earnings declined 6.0%.

As of June 30, 2026, NovoCure held $440.6M in cash and short-term investments against $233.4M in total debt, yielding net cash of $207.1M. The company reported a current ratio of 2.89, total assets of $795.2M, and shareholders' equity of $338.1M, representing a debt-to-equity ratio of 0.69. Operating cash flow in FY2025 was -$49.0M, and free cash flow was -$75.7M after capital expenditures of $26.6M. In addition, the five-year share count change stood at 11.7%.

At a last close price of $14.07 on October 16, 2026, NovoCure has a market cap of $1.64B and enterprise value of $1.69B. The stock trades at a price-to-sales ratio of 2.3x and an EV-to-revenue ratio of 2.4x. Its price-to-sales multiple sits below the median of its US-listed Healthcare peers of 4.1x, while its forward P/E of 909.1x exceeds the peer median of 17.3x. Over the past year, NVCR gained 0.3%, trailing the S&P 500 return of 16.8%, and over five years the stock fell 87.5% compared to an 83.0% gain for the S&P 500.

Wall Street coverage consists of 3 Strong Buy, 1 Buy, and 3 Hold recommendations, with zero Sell or Strong Sell ratings. The mean price target of $26.86 implies 90.9% upside compared to the last close of $14.07. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $726.1M and an EPS of -$1.24. For the next fiscal year, 7 analysts project revenue to increase 10.8% to $804.8M and EPS to reach -$0.81. NovoCure beat EPS estimates in 3 of the last 4 quarters, with its next earnings date set for October 29, 2026.

This page is an AI-written research summary of NovoCure Limited (NVCR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NVCR income statement, NVCR balance sheet, NVCR key metrics, NVCR analyst forecast, NVCR chart. See the NVCR stock overview for the latest quote and news.